Pfizer Inc. (NYSE:PFE) Shares Acquired by Cinctive Capital Management LP

Cinctive Capital Management LP grew its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 7.1% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 181,302 shares of the biopharmaceutical company's stock after buying an additional 12,060 shares during the period. Cinctive Capital Management LP's holdings in Pfizer were worth $4,810,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the business. Nordea Investment Management AB grew its stake in shares of Pfizer by 36.1% in the 4th quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company's stock valued at $108,002,000 after purchasing an additional 1,080,822 shares during the last quarter. Parsons Capital Management Inc. RI grew its position in Pfizer by 118.7% in the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock valued at $7,820,000 after buying an additional 159,984 shares during the last quarter. Copley Financial Group Inc. acquired a new position in Pfizer in the 3rd quarter valued at $577,000. Zacks Investment Management lifted its stake in shares of Pfizer by 10.9% in the 3rd quarter. Zacks Investment Management now owns 2,389,138 shares of the biopharmaceutical company's stock worth $69,142,000 after acquiring an additional 235,243 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Pfizer by 1.6% in the third quarter. Geode Capital Management LLC now owns 117,666,245 shares of the biopharmaceutical company's stock valued at $3,392,342,000 after acquiring an additional 1,855,419 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Remove Ads

Pfizer Trading Down 1.6 %

NYSE:PFE traded down $0.41 on Thursday, reaching $24.30. The stock had a trading volume of 53,412,700 shares, compared to its average volume of 39,310,365. Pfizer Inc. has a 12-month low of $24.26 and a 12-month high of $31.54. The company has a market cap of $137.79 billion, a price-to-earnings ratio of 17.23, a P/E/G ratio of 0.64 and a beta of 0.61. The firm's fifty day moving average is $25.93 and its two-hundred day moving average is $26.81. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company's quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.10 earnings per share. Equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the firm's stock in a transaction on Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 0.06% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Bank of America reaffirmed a "neutral" rating and issued a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Citigroup restated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Finally, UBS Group reduced their price objective on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have issued a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, Pfizer presently has an average rating of "Moderate Buy" and an average target price of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.